Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Pfizer
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
71High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT06075615CT.gov A Study to Learn About Dacomitnib in Patients With Non-small Cell Lung Cancer Which Has Spread to the Brain. | — | Withdrawn | — | — | — |
NCT05834348CT.gov A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway. | — | Completed | — | — | — |
NCT05271916CT.gov First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations | — | Recruiting | — | — | — |
NCT06486142CT.gov EGFR-mutated Lung Cancer in Randomized Investigator-Initiated Study | — | Recruiting | — | — | — |
NCT04946968CT.gov Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | — | Active Not Recruiting | — | — | — |
NCT04504071CT.gov Dacomitinib in Lung Cancer With Uncommon EGFR Mutations | — | Active Not Recruiting | — | — | — |
NCT04675008CT.gov Central Nervous System(CNS) Efficacy of Dacomitinib | — | Unknown | — | — | — |
NCT04575415CT.gov Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study | — | Unknown | — | — | — |
NCT04768491CT.gov Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC | — | Unknown | — | — | — |
NCT04511533CT.gov Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations | — | Completed | — | — | — |
Show 19 more trialsShow fewer
NCT04339829CT.gov An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases | — | Unknown | — | — | — |
NCT04811001CT.gov Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations | — | Unknown | — | — | — |
NCT04155541CT.gov Special Investigation for VIZIMPRO Tablets (Secondary Data Collection Study; Safety and Efficacy of VIZIMPRO Under Japanese Medical Practice) | — | Completed | — | — | — |
NCT04027647CT.gov Phase 2 Study of Dacomitinib in NSCLC | — | Active Not Recruiting | — | — | — |
NCT03810807CT.gov Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer | — | Completed | — | — | — |
NCT02382796CT.gov A Rollover Protocol of Dacomitinib For Patients In Japan | — | Completed | — | — | — |
NCT01918761CT.gov Dacomitinib + Pemetrexed for Patients With Advanced Non-squamous Non-small Cell Lung Cancer (NSCLC) | — | Terminated | — | — | — |
NCT01858389CT.gov A Study Of Dacomitinib (PF-00299804) In Patients With Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01774721CT.gov ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC. | — | Completed | — | — | — |
NCT01465802CT.gov Study Of Dacomitinib (PF-00299804) In Advanced NSCLC Patients (Post Chemo Or Select First Line) To Evaluate Prophylactic Intervention On Derm And GI AEs And PRO | — | Completed | — | — | — |
NCT01441128CT.gov -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer | — | Terminated | — | — | — |
NCT01360554CT.gov ARCHER 1009 : A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer | — | Completed | — | — | — |
NCT01121575CT.gov A Study Of Combined C- MET Inhibitor And PAN-HER Inhibitor (PF-02341066 And PF-00299804) In Patients With Non- Small Cell Lung Cancer | — | Completed | — | — | — |
NCT00971191CT.gov A Study In Patients Who Will Undergo Surgical Removal Of Non-Small Cell Lung Cancer To Evaluate Molecular Changes That Occur In Tumor Tissue After Short Term Exposure To PF-00299804 | — | Terminated | — | — | — |
NCT00818441CT.gov Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung | — | Completed | — | — | — |
NCT00728390CT.gov A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 Weeks | — | Completed | — | — | — |
NCT00769067CT.gov A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy Regimen | — | Completed | — | — | — |
NCT00548093CT.gov PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And Erlotinib | — | Completed | — | — | — |
NCT00553254CT.gov Trial Of PF-00299804 In Patients With Advanced Refractory Lung Cancer | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Non-Small Cell Lung Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Dacomitinib (this asset) | Pfizer | Approved | BB · 69 |
| Necitumumab | Jonsson Comprehensive Cancer Center | P3 | BBB |
| Glumetinib | Shanghai JMT-Bio Inc. | P3 | BBB |
| Veliparib | AbbVie | P3 | BBB |
| d-0316 | Betta Pharmaceuticals Co., Ltd. | P2/3 | BBB |
| Icotinib | The First Affiliated Hospital of Guangzhou Medical University | P4 | BBB |
| Zoledronate | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | P4 | BBB |
| Onartuzumab | Hoffmann-La Roche | P3 | BBB |
| Avitinib | Hangzhou ACEA Pharmaceutical Research Co., Ltd. | P3 | BBB |
+42 more in the Non-Small Cell Lung Carcinoma cohort
Other indications for Dacomitinib
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Brain Neoplasm | — | P2 | B · 57 |
| Lung Cancer | — | P3 | CCC · 54 |
| Glioblastoma | — | P2 | CCC · 54 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Dacomitinib in Non-Small Cell Lung Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/dacomitinib-non-small-cell-lung-carcinoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →